Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 13 (8), e0200204
eCollection

Meta-analysis of Postoperative Adjuvant Therapy for Small Bowel Adenocarcinoma

Affiliations
Review

Meta-analysis of Postoperative Adjuvant Therapy for Small Bowel Adenocarcinoma

Xiaojian Ye et al. PLoS One.

Erratum in

Abstract

Objective: The role of adjuvant therapy in small bowel adenocarcinoma (SBA), a rare malignancy with a poor prognosis, is controversial. The purpose of this article is to investigate the impact of adjuvant therapy on the survival of patients with SBA in a meta-analysis.

Methods: We performed a comprehensive search of PubMed, EMBASE and the Cochrane Library database between 2010 and 2017. Hazard ratios (HR) with 95% confidence intervals (95%CI) were used to assess the effect of adjuvant chemotherapy and/or radiation treatment after curative surgery in patients with SBA. Moreover, impact of age, sex, stage, differentiation, lymph node involvement, and margin status was also evaluated.

Results: We included 15 studies to evaluate the effect of adjuvant therapy on the survival of patients with SBA. The pooled HR of overall survival (OS) involving 5986 patients showed that adjuvant therapy did not have a statistically significant effect on the survival of patients with SBA (pooled HR = 0.89, 95% CI = 0.73-1.09, p = 0.25). Further, 607 patients with duodenal adenocarcinoma (DA) had similar results (pooled HR = 0.96, 95% CI = 0.75-1.23, p = 0.77). Similarly, adjuvant treatment vs. non-adjuvant treatment in terms of disease-free survival (DFS) or relapse-free survival (RFS) showed the same results (pooled HR = 0.89, 95% CI = 0.64-1.23, p = 0.48). However, we found that adjuvant therapy resulted in favorable postoperative survival in Europe according to the subgroup analysis (pooled HR = 0.63, 95% CI = 0.5-0.8, p = 0.0002). In addition, the pooled HR shows that stage, differentiation, lymph node involvement, and margin status were related to the OS of patients with SBA.

Conclusion: Patients with SBA who received adjuvant therapy after surgery did not receive a significant survival benefit. Adjuvant therapy may be more useful in advanced cancer or metastatic patients.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Meta-analysis flow diagram.
Fig 2
Fig 2. Forest plots to assess the effect of adjuvant therapy on the overall survival of patients with small bowel adenocarcinoma.
Fig 3
Fig 3. Forest plots to assess the effect of adjuvant therapy on the recurrence of patients with small bowel adenocarcinoma.
Fig 4
Fig 4. Begg`’s funnel plots to evaluate publication bias in related studies.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Haselkorn T, Whittemore AS, Lilienfeld DE (2005) Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control 16: 781–787. 10.1007/s10552-005-3635-6 - DOI - PubMed
    1. Ecker BL, McMillan MT, Datta J, Lee MK, Karakousis GC, Vollmer C J, et al. (2017) Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database. Cancer 123: 967–976. 10.1002/cncr.30439 - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. (2014) SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute.
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71–96. 10.3322/CA.2007.0010 - DOI - PubMed
    1. Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S, et al. (2014) Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis 46: 97–104. 10.1016/j.dld.2013.04.013 - DOI - PubMed

Grant support

This study was supported by the Graduate Student Innovation Special Fund Project of Nanchang University (CX2016063) to XJY. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Feedback